trazodone has been researched along with Cardiac Toxicity in 2 studies
Trazodone: A serotonin uptake inhibitor that is used as an antidepressive agent. It has been shown to be effective in patients with major depressive disorders and other subsets of depressive disorders. It is generally more useful in depressive disorders associated with insomnia and anxiety. This drug does not aggravate psychotic symptoms in patients with schizophrenia or schizoaffective disorders. (From AMA Drug Evaluations Annual, 1994, p309)
trazodone : An N-arylpiperazine in which one nitrogen is substituted by a 3-chlorophenyl group, while the other is substituted by a 3-(3-oxo[1,2,4]triazolo[4,3-a]pyridin-2(3H)-yl)propyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Trazodone (TRZ) is an antidepressant drug commonly used in the treatment of depression, anxiety, and insomnia." | 5.51 | Assessment of trazodone-induced cardiotoxicity after repeated doses in rats. ( Atli, O; Baysal, M; Gormus, G; Ilgin, S; Kilic, G; Kilic, V; Korkut, B; Ucarcan, S, 2019) |
| " To elucidate the cellular mechanism for the adverse cardiac effects of trazodone, we investigated its effects on cardiac APs and ion channels using whole-cell patch clamp techniques in human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) and transiently transfected human embryonic kidney cells (HEK293) with cardiac ion channel complementary DNA." | 5.43 | Cellular mechanisms for trazodone-induced cardiotoxicity. ( Kim, KS; Kim, SJ; Lee, HA; Lee, S, 2016) |
| "Trazodone (TRZ) is an antidepressant drug commonly used in the treatment of depression, anxiety, and insomnia." | 1.51 | Assessment of trazodone-induced cardiotoxicity after repeated doses in rats. ( Atli, O; Baysal, M; Gormus, G; Ilgin, S; Kilic, G; Kilic, V; Korkut, B; Ucarcan, S, 2019) |
| " To elucidate the cellular mechanism for the adverse cardiac effects of trazodone, we investigated its effects on cardiac APs and ion channels using whole-cell patch clamp techniques in human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) and transiently transfected human embryonic kidney cells (HEK293) with cardiac ion channel complementary DNA." | 1.43 | Cellular mechanisms for trazodone-induced cardiotoxicity. ( Kim, KS; Kim, SJ; Lee, HA; Lee, S, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Atli, O | 1 |
| Kilic, V | 1 |
| Baysal, M | 1 |
| Kilic, G | 1 |
| Gormus, G | 1 |
| Ucarcan, S | 1 |
| Korkut, B | 1 |
| Ilgin, S | 1 |
| Lee, S | 1 |
| Lee, HA | 1 |
| Kim, SJ | 1 |
| Kim, KS | 1 |
2 other studies available for trazodone and Cardiac Toxicity
| Article | Year |
|---|---|
Assessment of trazodone-induced cardiotoxicity after repeated doses in rats.
Topics: Administration, Oral; Animals; Antidepressive Agents, Second-Generation; Aspartate Aminotransferases | 2019 |
Cellular mechanisms for trazodone-induced cardiotoxicity.
Topics: Action Potentials; Antidepressive Agents, Second-Generation; Cardiotoxicity; Cell Culture Techniques | 2016 |